227 related articles for article (PubMed ID: 38132167)
41. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
42. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Saiki M; Kitazono S; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Yanagitani N; Horiike A; Ohyanagi F; Oikado K; Ninomiya H; Takeuchi K; Ishikawa Y; Nishio M
Clin Lung Cancer; 2018 Sep; 19(5):435-440.e1. PubMed ID: 29885946
[TBL] [Abstract][Full Text] [Related]
44. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
[TBL] [Abstract][Full Text] [Related]
45. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
46. Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer.
Gao M; Zhang X; Yan H; Sun D; Yang X; Yuan F; Ju Y; Wang L; Wang J; Zhao W; Zhang D; Li L; Xu X; Ma J; Hu Y; Zhang X
Support Care Cancer; 2023 Nov; 31(12):671. PubMed ID: 37924363
[TBL] [Abstract][Full Text] [Related]
47. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
49. RET-rearranged non-small-cell lung cancer and therapeutic implications.
Loh Z; Mitchell P; John T; Arulananda S
Intern Med J; 2019 Dec; 49(12):1541-1545. PubMed ID: 31808254
[TBL] [Abstract][Full Text] [Related]
50. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
51. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
[TBL] [Abstract][Full Text] [Related]
52. Establishment of an induced pluripotent stem cell model of Hirschsrpung disease, a congenital condition of the enteric nervous system, from a patient carrying a novel RET mutation.
Wang Y; Lai X; Huang L; Liu G; Zai Z; Zhu D; Zhang Y; Liang Z; Yao Z; Chen Y; Wen Z; Xia H
Neuroreport; 2018 Aug; 29(12):975-980. PubMed ID: 29965875
[TBL] [Abstract][Full Text] [Related]
53. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X; Xu C; Wang Q; Wang W; Wu F; Cai X; Song Z; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Pang F; Huang J; Wang K; Wu F; Shen T; Zou S; Xu B; Wang L; Zhu Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Fu J; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Lan G; Yang S; Shi L; Wang Y; Li B; Zhang Z; Li Z; Li Y; Liu Z; Yang N; Wang H; Huang W; Hong Z; Wang G; Wang J; Fang M; Fang Y; Zhu X; Shen Y; Zhang Y; Ma S; Song Y; Lu Y; Fang W; Li Z; Wu L
Thorac Cancer; 2023 Nov; 14(31):3166-3177. PubMed ID: 37718634
[TBL] [Abstract][Full Text] [Related]
54. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
55. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
56. The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.
Yang Z; Qi X; Gross N; Kou X; Bai Y; Feng Y; Wang B; Zafereo ME; Li G; Sun C; Li H; Chen X; Huang Z
J Cell Mol Med; 2020 Nov; 24(22):13163-13170. PubMed ID: 32989896
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
Zhang Q; Xu C; Wang W; Wu M; Zhu Y; Zhuang W; Du K; Huang Y; Chen Y; Wu B
Med Sci Monit; 2018 Nov; 24():8207-8212. PubMed ID: 30429449
[TBL] [Abstract][Full Text] [Related]
58. Pralsetinib treatment for multiple
Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
[TBL] [Abstract][Full Text] [Related]
59. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
60. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
